Key result
LPS plus PAR-2 agonists synergistically potentiates IL-8 release and upregulates PAR-2 in airway epithelial cells.
Why the study?
The role of PAR-2 and its interaction with LPS in regulating PAR expression and IL-8 release in airway epithelial cells was not fully understood.
PAR-2 activation and LPS synergistically enhance inflammatory signaling in airway epithelial cells, highlighting the role of PAR-2 in lung inflammation.
May implicate PAR-2 in LPS-driven airway inflammation; leaves open therapeutic relevance in human lung disease.
Protease-activated receptors (PARs) are involved in the contribution of airway epithelial cells to the development of inflammation by release of pro- and anti-inflammatory mediators. Here, we evaluated in epithelial cells the influence of LPS and continuous PAR activation on PAR expression level and the release of the proinflammatory chemokine IL-8. We studied primary human small airway epithelial cells and two airway epithelial cell lines, A549 and HBE cells. LPS specifically upregulated expression of PAR-2 but not of PAR-1. Exposure of epithelial cells to PAR-1 or PAR-2 agonists increased the PAR-1 expression level. The PAR-2 agonist exhibited higher potency than PAR-1 activators. However, the combined exposure of epithelial cells to LPS and PAR agonists abrogated the PAR-1 upregulation. The PAR-2 expression level was also upregulated after exposure to PAR-1 or PAR-2 agonists. This elevation was higher than the effect of PAR agonists on the PAR-1 level. In contrast to the PAR-1 level, the PAR-2 level remained elevated under concomitant stimulation with LPS and PAR-2 agonist. Furthermore, activation of PAR-2, but not of PAR-1, caused production of IL-8 from the epithelial cells. Interestingly, both in the epithelial cell line and in primary epithelial cells, there was a potentiation of the stimulation of the IL-8 synthesis and release by PAR-2 agonist together with LPS. In summary, these results underline the important role of PAR-2 in human lung epithelial cells. Moreover, our study shows an intricate interplay between LPS and PAR agonists in affecting PAR regulation and IL-8 production.
No takes yet. Share an insight, caveat, or question.
Ostrowska et al. (2007) studied Airway inflammation. LPS and PAR agonists was evaluated on PAR expression level and IL-8 release. Combined exposure of airway epithelial cells to LPS and PAR-2 agonists synergistically potentiated IL-8 synthesis and release, and upregulated PAR-2 expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: